IL130377A0 - Diaza-spiro¬3,5¾nonane derivatives - Google Patents

Diaza-spiro¬3,5¾nonane derivatives

Info

Publication number
IL130377A0
IL130377A0 IL13037799A IL13037799A IL130377A0 IL 130377 A0 IL130377 A0 IL 130377A0 IL 13037799 A IL13037799 A IL 13037799A IL 13037799 A IL13037799 A IL 13037799A IL 130377 A0 IL130377 A0 IL 130377A0
Authority
IL
Israel
Prior art keywords
diaza
spiro
derivatives
Prior art date
Application number
IL13037799A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL130377A0 publication Critical patent/IL130377A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
IL13037799A 1998-06-12 1999-06-09 Diaza-spiro¬3,5¾nonane derivatives IL130377A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98110804 1998-06-12

Publications (1)

Publication Number Publication Date
IL130377A0 true IL130377A0 (en) 2000-06-01

Family

ID=8232114

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13037799A IL130377A0 (en) 1998-06-12 1999-06-09 Diaza-spiro¬3,5¾nonane derivatives

Country Status (28)

Country Link
US (1) US6113527A (OSRAM)
EP (1) EP0970957B1 (OSRAM)
JP (1) JP3286268B2 (OSRAM)
KR (1) KR100344732B1 (OSRAM)
CN (1) CN1107066C (OSRAM)
AR (1) AR019859A1 (OSRAM)
AT (1) ATE204279T1 (OSRAM)
AU (1) AU743983B2 (OSRAM)
BR (1) BR9902651A (OSRAM)
CA (1) CA2274202A1 (OSRAM)
DE (1) DE69900220T2 (OSRAM)
DK (1) DK0970957T3 (OSRAM)
ES (1) ES2162503T3 (OSRAM)
HR (1) HRP990188A2 (OSRAM)
HU (1) HU220894B1 (OSRAM)
ID (1) ID23304A (OSRAM)
IL (1) IL130377A0 (OSRAM)
MA (1) MA26644A1 (OSRAM)
NO (1) NO312590B1 (OSRAM)
NZ (1) NZ336189A (OSRAM)
PE (1) PE20000548A1 (OSRAM)
PL (1) PL333695A1 (OSRAM)
PT (1) PT970957E (OSRAM)
SG (1) SG79259A1 (OSRAM)
SI (1) SI0970957T1 (OSRAM)
TR (1) TR199901381A2 (OSRAM)
YU (1) YU26499A (OSRAM)
ZA (1) ZA993852B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406629A1 (en) * 2001-07-02 2004-04-14 Omeros Corporation Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
US7566728B2 (en) * 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
JP2005289816A (ja) 2002-05-14 2005-10-20 Banyu Pharmaceut Co Ltd ベンズイミダゾール誘導体
WO2004005293A2 (en) * 2002-07-05 2004-01-15 Targacept, Inc. N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
EA009369B1 (ru) * 2002-09-09 2007-12-28 Янссен Фармацевтика, Н.В. Производные гидроксизамещенного 1,3,8-триазинспиро[4,5]декан-4-она, полезные для лечения расстройств, опосредованных orl-рецептором
GB0323204D0 (en) * 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050228023A1 (en) * 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
UA92327C2 (ru) * 2004-08-20 2010-10-25 Таргасепт, Инк. Применение n-арилдиазаспироциклических соединений для лечения зависимостей
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
MX2009005641A (es) * 2006-11-28 2009-06-05 Janssen Pharmaceutica Nv Sales de 3-(3-amino-2-(r)-hidroxi-propil)-1-(4-fluoro-fenil)-8-(8- metil-naftalen-1-ilmetil)-1,3,8-triaza-espiro[4,5]deca n-4-ona.
CN101679430B (zh) * 2007-04-09 2013-12-25 詹森药业有限公司 用于治疗焦虑和抑郁症的作为orl-1受体的配体的1,3,8-三取代-1,3,8-三氮杂-螺[4.5]癸-4-酮衍生物
KR101704226B1 (ko) 2015-06-30 2017-02-07 현대자동차주식회사 자동차의 쿼터글라스 어셈블리
MX2024007780A (es) * 2021-12-22 2024-09-11 Univ California Inhibidores de unión covalente de mutantes g12s, g12d y/o g12e de k-ras gtpasa.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756743A (en) * 1996-04-10 1998-05-26 Hoechst Marion Roussel Inc. Spiro cyclopent b!indole-piperidines!

Also Published As

Publication number Publication date
JP3286268B2 (ja) 2002-05-27
KR20000006060A (ko) 2000-01-25
NO992873L (no) 1999-12-13
HU9901911D0 (en) 1999-08-30
NZ336189A (en) 2000-10-27
CA2274202A1 (en) 1999-12-12
DE69900220T2 (de) 2002-05-08
ES2162503T3 (es) 2001-12-16
JP2000053679A (ja) 2000-02-22
HRP990188A2 (en) 2000-02-29
AR019859A1 (es) 2002-03-20
DK0970957T3 (da) 2001-12-03
YU26499A (sh) 2002-09-19
TR199901381A3 (tr) 2000-01-21
SG79259A1 (en) 2001-03-20
CN1107066C (zh) 2003-04-30
CN1242366A (zh) 2000-01-26
ID23304A (id) 2000-04-05
BR9902651A (pt) 2000-05-16
SI0970957T1 (OSRAM) 2001-12-31
AU3498799A (en) 1999-12-23
ATE204279T1 (de) 2001-09-15
TR199901381A2 (xx) 2000-01-21
PL333695A1 (en) 1999-12-20
EP0970957B1 (en) 2001-08-16
DE69900220D1 (de) 2001-09-20
US6113527A (en) 2000-09-05
AU743983B2 (en) 2002-02-14
EP0970957A1 (en) 2000-01-12
PE20000548A1 (es) 2000-07-15
HU220894B1 (en) 2002-06-29
KR100344732B1 (ko) 2002-07-19
NO992873D0 (no) 1999-06-11
ZA993852B (en) 1999-12-13
NO312590B1 (no) 2002-06-03
MA26644A1 (fr) 2004-12-20
HUP9901911A1 (hu) 2000-05-28
PT970957E (pt) 2002-02-28

Similar Documents

Publication Publication Date Title
HU9800138D0 (en) 8-substituted-1,3,8-triaza-spiro [4,5]-decan-4-on derivatives
DE69941083D1 (en) 12,13-cyclopropan-epothilonderivate
IL141226A0 (en) 1h-imidazopyridine derivatives
PL345540A1 (en) Thiobenzimidazole derivatives
IL128027A0 (en) Benzosulfone derivatives
SI0921125T1 (en) 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
GB9910384D0 (en) Alpha-ketoamide derivatives
SG71173A1 (en) 1,3,8,-triaza-spiro[4,5]decan-4-on derivatives
IL134220A0 (en) 6,9-bridged erythromycin derivatives
IL134996A0 (en) 6,11-bridged erythromycin derivatives
IL130377A0 (en) Diaza-spiro¬3,5¾nonane derivatives
ZA982969B (en) 1,2,3,4-tetrahydro-benzofuro[3,2-c]pyridine derivatives.
PL342060A1 (en) Derivatives of 1,3,4-oxadiaxolone
EG23802A (en) 2-Phenylpyran-4-one derivatives
GB9827729D0 (en) Thieno-indole derivatives
EP1061912A4 (en) PHENANTHROFURANDERIVATE
SG81317A1 (en) Figure toy
IL139276A0 (en) Cyclohexenondioxthio chromanoyl derivatives
GB2350361B (en) 3,4,5-tricyanophenyl derivatives
PL352760A1 (en) Oxathiepino[6,5-b
GB9816279D0 (en) Arylthiazolidinedione derivatives
SI1051395T1 (sl) N-hidroksiformamidni derivati
ZA9811564B (en) Derivatives of 1,3,4-oxadiazolone
ZA200101452B (en) 1-H-Imidazopyridine derivatives.
GB9815537D0 (en) 2,6-Quinolines